Vir Biotechnology executive sells over 27k in company stock
| VIR Stock | USD 4.60 0.05 1.10% |
Slightly above 56% of Vir Biotechnology's investor base is looking to short. The analysis of the overall investor sentiment regarding Vir Biotechnology suggests that many traders are alarmed. Vir Biotechnology's investing sentiment overview a quick insight into current market opportunities from investing in Vir Biotechnology. Many technical investors use Vir Biotechnology stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Vir Biotechnology executive sells over 27k in company stock
Read at investing.com
 |
Vir Biotechnology Fundamental Analysis
We analyze Vir Biotechnology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Vir Biotechnology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Vir Biotechnology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Shares Owned By Institutions
Shares Owned By Institutions Comparative Analysis
Vir Biotechnology is currently under evaluation in shares owned by institutions category among its peers. Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.
Vir Biotechnology Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Vir Biotechnology stock to make a market-neutral strategy. Peer analysis of Vir Biotechnology could also be used in its relative valuation, which is a method of valuing Vir Biotechnology by comparing valuation metrics with similar companies.
Peers
Vir Biotechnology Related Equities
| CVAC | CureVac NV | 8.45 | ||||
| PPCB | Propanc Biopharma | 7.14 | ||||
| AMLX | Amylyx Pharmaceuticals | 7.08 | ||||
| VKTX | Viking Therapeutics | 3.76 | ||||
| TERN | Terns Pharmaceuticals | 3.23 | ||||
| BPMC | Blueprint Medicines | 2.21 | ||||
| PTCT | PTC Therapeutics | 1.54 | ||||
| DAWN | Day One | 1.46 | ||||
| KRYS | Krystal Biotech | 0.21 | ||||
| MDGL | Madrigal Pharmaceuticals | 0.29 | ||||
| AKRO | Akero Therapeutics | 2.73 |
Additional Tools for Vir Stock Analysis
When running Vir Biotechnology's price analysis, check to measure Vir Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vir Biotechnology is operating at the current time. Most of Vir Biotechnology's value examination focuses on studying past and present price action to predict the probability of Vir Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vir Biotechnology's price. Additionally, you may evaluate how the addition of Vir Biotechnology to your portfolios can decrease your overall portfolio volatility.